2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)

JAMA The Journal of the American Medical Association (Impact Factor: 35.29). 12/2013; 311(5). DOI: 10.1001/jama.2013.284427
Source: PubMed

ABSTRACT Hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal failure, and death if not detected early and treated appropriately. Patients want to be assured that blood pressure (BP) treatment will reduce their disease burden, while clinicians want guidance on hypertension management using the best scientific evidence. This report takes a rigorous, evidence-based approach to recommend treatment thresholds, goals, and medications in the management of hypertension in adults. Evidence was drawn from randomized controlled trials, which represent the gold standard for determining efficacy and effectiveness. Evidence quality and recommendations were graded based on their effect on important outcomes. There is strong evidence to support treating hypertensive persons aged 60 years or older to a BP goal of less than 150/90 mm Hg and hypertensive persons 30 through 59 years of age to a diastolic goal of less than 90 mm Hg; however, there is insufficient evidence in hypertensive persons younger than 60 years for a systolic goal, or in those younger than 30 years for a diastolic goal, so the panel recommends a BP of less than 140/90 mm Hg for those groups based on expert opinion. The same thresholds and goals are recommended for hypertensive adults with diabetes or nondiabetic chronic kidney disease (CKD) as for the general hypertensive population younger than 60 years. There is moderate evidence to support initiating drug treatment with an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker, or thiazide-type diuretic in the nonblack hypertensive population, including those with diabetes. In the black hypertensive population, including those with diabetes, a calcium channel blocker or thiazide-type diuretic is recommended as initial therapy. There is moderate evidence to support initial or add-on antihypertensive therapy with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in persons with CKD to improve kidney outcomes. Although this guideline provides evidence-based recommendations for the management of high BP and should meet the clinical needs of most patients, these recommendations are not a substitute for clinical judgment, and decisions about care must carefully consider and incorporate the clinical characteristics and circumstances of each individual patient.

Download full-text


Available from: Gbenga Ogedegbe, Mar 04, 2014
345 Reads
  • Source
    • "Even a small reduction in the mean blood pressure of a population can lead to a decrease in cardiovascular morbidity and mortality [14]. Therefore, for prevention and management of hypertension, the American Heart, Lung and Blood Institute recommends adherence to the DASH (Dietary Approaches to Stop Hypertension) dietda diet based on low intake of sodium and fat, and high intake of fruits and vegetables [12] [14]. The European Society of Hypertension also recommends a decrease in the intake of sodium and fat, and an increase in the consumption of vegetables and fruits to lower blood pressure levels [15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to investigate the association between hypertension and kimchi, a salt-fermented vegetable, intake.
    12/2014; 1(1):8-12. DOI:10.1016/j.jef.2014.11.004
  • Source
    • "In our study, participants who attended a screening visit were more likely to have subsequent claims for hypertension, diabetes and dyslipidemia in the following year, confirming that increased detection of CVD-related health conditions lead to subsequent care (James et al., 2014; Lackland et al., 2014). Similar results have been found in a cohort study in Taiwan (Lin et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine whether a cardiovascular disease (CVD) health screening program is associated with CVD-related health conditions, incidence of cardiovascular events, mortality, healthcare utilization, and costs. Cohort study of a 3% random sample of all Korea National Health Insurance members 40years of age or older and free of CVD or CVD-related health conditions was conducted. A total 443,337 study participants were followed-up from January 1, 2005 through December 31, 2010. In primary analysis, the hazard ratios for CVD mortality, all-cause mortality, incident composite CVD events, myocardial infarction, cerebral infarction, and cerebral hemorrhage comparing participants who attended a screening exam during 2003-2004 compared to those who did not were 0.58 (95% CI: 0.53-0.63), 0.62 (95% CI: 0.60-0.64), 0.82 (95% CI: 0.78-0.85), 0.84 (95% CI: 0.75-0.93), 0.84 (95% CI: 0.79-0.89), and 0.73 (95% CI: 0.67-0.80), respectively. Screening attenders had higher rates of newly diagnosed hypertension, diabetes mellitus, and dyslipidemia, lower inpatient days of stay and cost, and lower outpatient cost compared to non-attenders. Participation in CVD health screening was associated with lower rates of CVD, all-cause mortality, and CVD events, higher detection of CVD-related health conditions, and lower healthcare utilization and costs. Copyright © 2014. Published by Elsevier Inc.
    Preventive Medicine 11/2014; 70C:19-25. DOI:10.1016/j.ypmed.2014.11.007 · 3.09 Impact Factor
  • Source
    • "It has been demonstrated that even people who are free of hypertension (BP < 140/90 mm Hg) at the age of 55 have a 90% lifetime risk for developing hypertension, according to the Framingham data3. In addition, accumulating evidence suggest that health-promoting lifestyle modifications can improve blood pressure (BP) control and even reduce medication needs4. Among the comprehensive lifestyle modifications, dietary adjustment is one of the most effective measures for preventing hypertension. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The studies investigating the effects of green tea on blood pressure (BP) have generated inconsistent results. The aim of this study is to quantitatively evaluate the effects of green tea on BP control. PubMed, Embase, and the Cochrane Library (updated to March 2014) were searched for randomized controlled trials evaluating the effects of green tea on BP. Pooled effect of green tea consumption on BP was evaluated using fixed-effects or random-effects model. Thirteen trials comprising a total of 1,367 subjects were included in the current meta-analysis. The overall outcome of the meta-analysis suggested that green tea consumption significantly decrease systolic blood pressure (SBP) level by -1.98 mmHg (95% CI: -2.94, -1.01 mmHg; P < 0.001). Compared with the control group, green tea also showed a significant lowering effect on diastolic blood pressure (DBP) in treatment group (-1.92 mmHg; 95% CI: -3.17, -0.68 mmHg; P = 0.002). Subgroup analyses further suggested that the positive effect of green tea polyphenols on BP was only showed in studies using a low-dose green tea polyphenol, with the long-term intervention duration or ruling out the confounding effects of caffeine. The meta-analysis suggested that green tea consumption had a favorable effect on decrease of BP.
    Scientific Reports 09/2014; 4:6251. DOI:10.1038/srep06251 · 5.58 Impact Factor
Show more